Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
RPTH Journal shared a post on LinkedIn about a recent article by Jurjen Krommenhoek et al., published in RPTH Journal, adding:
“Does reversing factor Xa inhibitors really carry as much thrombotic risk as we think?
Real-world data from the Netherlands offer a reassuring perspective.
Among 217 patients treated with andexanet alfa, the 30-day thrombotic event rate was just 4.6%, substantially lower than reported in major clinical trials.
Even more striking, no thrombotic events occurred after anticoagulation was restarted, reinforcing the importance of timely reinitiation when clinically appropriate.
A valuable real-world look at balancing life-saving bleeding reversal with thrombotic risk.”
Title: Andexanet alfa for the reversal of anticoagulation: Dutch practice data
Authors: Jurjen F Krommenhoek, Wendy Beekman, Flip Kor, Pim Gal, Willemijn E M Berkhout, Karina Meijer, Dionne C W Braeken, Frederikus A Klok, Hugo ten Cate, Renske H Olie
Other articles featuring RPTH Journal on Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?